Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 4/2012

01-08-2012 | Case Report

Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies

Authors: Shinji Sato, Masataka Kuwana, Takashi Fujita, Yasuo Suzuki

Published in: Modern Rheumatology | Issue 4/2012

Login to get access

Abstract

Anti-clinically amyopathic dermatomyositis (CADM)-140/MDA5 autoantibodies are specifically detected in patients with dermatomyositis and are known to have a strong association with rapidly progressive interstitial lung disease (RP-ILD). Here we report an amyopathic dermatomyositis (ADM) patient who developed RP-ILD characterized by elevated anti-CADM-140/MDA5 titer. Respiratory symptoms gradually improved, and anti-CADM-140/MDA5 titer decreased in parallel to below the cutoff level. It may be useful to quantify CADM-140-specific autoantibodies for monitoring disease activity in patients with ADM and RP-ILD.
Literature
1.
Pearson CM. Polymyositis and dermatomyositis. In: McCarty DJ, editor. Arthritis and allied condition. 9th ed. Philadelphia: Lea and Febiger; 1979. p. 742.
2.
Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626–36.PubMedCrossRef
3.
Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med. 1986;80:329–32.PubMedCrossRef
4.
Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol. 1999;18:462–7.PubMedCrossRef
5.
Nagatomo Y, Okayama A, Murai K, Sasaki T, Kuroki M, Tanaka G, et al. Successful treatment using high-dose intravenous immunoglobulin in a patient with rapidly progressive interstitial pneumonia associated with dermatomyositis. Mod Rheumatol. 2000;10:165–8.CrossRef
6.
Chow SK, Yeap SS. Amyopathic dermatomyositis and pulmonary fibrosis. Clin Rheumatol. 2000;19:484–5.PubMedCrossRef
7.
Miyake S, Ohtani Y, Sawada M, Inase N, Miyazaki Y, Takano S, et al. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:128–33.PubMed
8.
Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol. 2002;21:391–6.PubMedCrossRef
9.
High WA, Cohen JB, Murphy BA, Costner MI. Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis. J Am Acad Dermatol. 2003;49:295–8.PubMedCrossRef
10.
Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44:1282–6.CrossRef
11.
Neuhaus IM, Connolly MK. An unusual presentation of amyopathic dermatomyositis associated with fatal interstitial lung disease. Arch Dermatol. 2006;142:113–4.PubMedCrossRef
12.
Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28:1005–12.PubMedCrossRef
13.
Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647–54.PubMedCrossRef
14.
Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuno O, Nureki S, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007;26:436–9.PubMedCrossRef
15.
Ideura G, Hanaoka M, Koizumi T, Fujimoto K, Shimojima Y, Ishii W, et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med. 2007;101:1406–11.PubMedCrossRef
16.
Kakugawa T, Mukae H, Saito M, Ishii K, Ishimoto H, Sakamoto N, et al. Rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intern Med. 2008;47:785–90.PubMedCrossRef
17.
Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.PubMedCrossRef
18.
Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2010 Nov 5. Epub ahead of print.
19.
Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193–200.PubMedCrossRef
20.
Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105:1380–7.PubMedCrossRef
21.
Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25–34.PubMedCrossRef
Metadata
Title
Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies
Authors
Shinji Sato
Masataka Kuwana
Takashi Fujita
Yasuo Suzuki
Publication date
01-08-2012
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 4/2012
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-011-0558-9

Other articles of this Issue 4/2012

Modern Rheumatology 4/2012 Go to the issue

Case Report

Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab

Original Article

Prospective monitoring of Epstein–Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab

Rapid Communication

Radiographic remodeling of the shoulder joint in a patient with rheumatoid arthritis after 4 years of treatment with etanercept

Original Article

Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms

Original Article

Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and polyarthritis

Original Article

The role of resistin in Behçet’s disease: a Turkish experiment
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits